About atara biotherapeutics inc. - ATRA
Atara Biotherapeutics, Inc. is an allogeneic T-cell immunotherapy company, which engages in the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. It also delivers off-the-shelf treatments to patients with high unmet medical need. Its product pipeline includes Tab-cel, ATA188, ATA2271/ATA3271, and ATA3219. The company was founded by Isaac E. Ciechanover on August 22, 2012 and is headquartered in Thousand Oaks, CA.
ATRA At a Glance
Atara Biotherapeutics, Inc.
1280 Rancho Conejo Boulevard
Thousand Oaks, California 91320
| Phone | 1-805-623-4211 | Revenue | 120.77M | |
| Industry | Pharmaceuticals: Major | Net Income | 32.69M | |
| Sector | Health Technology | Employees | 14 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
ATRA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 7.038 |
| Price to Sales Ratio | 1.905 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 5.288 |
| Enterprise Value to Sales | 2.272 |
| Total Debt to Enterprise Value | 0.192 |
ATRA Efficiency
| Revenue/Employee | 8,626,571.429 |
| Income Per Employee | 2,334,857.143 |
| Receivables Turnover | 96.386 |
| Total Asset Turnover | 1.844 |
ATRA Liquidity
| Current Ratio | 0.818 |
| Quick Ratio | 0.818 |
| Cash Ratio | 0.568 |
ATRA Profitability
| Gross Margin | 82.436 |
| Operating Margin | 41.21 |
| Pretax Margin | 27.092 |
| Net Margin | 27.066 |
| Return on Assets | 49.91 |
| Return on Equity | N/A |
| Return on Total Capital | 228.651 |
| Return on Invested Capital | N/A |
ATRA Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | 369.32 |
| Total Debt to Total Assets | 241.186 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | 293.928 |